基因组瘢痕评分:基于基因组不稳定性预测同源重组缺陷的稳健模型
本研究开发了基于线性支持向量机的基因组瘢痕评分(GSS)模型,用于预测同源重组缺陷(HRD)。在377例卵巢癌或乳腺癌样本中,GS模型对BRCA缺陷事件的检测灵敏度超过97.0%。在58例接受PARP抑制剂治疗的卵巢癌患者中,GSS阳性组的中位无进展生存期(PFS)为9.4个月,优于GSS阴性组的4.4个月(HR=0.54,P<0.001)。
要点
- GS模型对BRCA缺陷事件的检测灵敏度超过97.0%。
- GSS阳性组接受PARP抑制剂治疗后中位PFS为9.4个月,GSS阴性组为4.4个月(HR=0.54,P<0.001)。
- GSS在不同NGS panel间显示高度一致性,提示模型稳健。
核心结论
- 基因组瘢痕(GS)是预测同源重组缺陷(HRD)的稳健模型,在预测哪些患者对PARP抑制剂治疗反应良好方面具有广泛的临床应用前景。
研究设计与样本
- 方法开发研究,使用线性支持向量机构建基因组瘢痕(GS)模型以预测HRD事件。
- 研究样本包括来自AmoyDx医学实验室的377例卵巢癌或乳腺癌个体,以及来自江苏省肿瘤医院的58例接受PARP抑制剂治疗的卵巢癌患者。
- 采用Kaplan-Meier分析和双侧log-rank检验比较不同组患者的无进展生存期(PFS)。
主要发现
- GS模型对BRCA缺陷事件的检测灵敏度超过97.0%。
- 接受PARP抑制剂治疗后,GSS阳性组的中位PFS为9.4个月,GSS阴性组为4.4个月(HR=0.54,P<0.001)。
- GSS在不同NGS panel间显示高度一致性,提示GS模型的稳健性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To develop a novel machine learning-based algorithm called the Genomic Scar Score (GSS) for predicting homologous recombination deficiency (HRD) events. DESIGN: Method development study. SETTING: AmoyDx Medical Laboratory and Jiangsu Cancer Hospital. POPULATION OR SAMPLE: A cohort of individuals with ovarian or breast cancer (n = 377) were collected from the AmoyDx Medical Laboratory. Another cohort of patients with ovarian cancer treated with PARP inhibitors (n = 58) was enrolled in the Jiangsu Cancer Hospital. METHODS: We used linear support vector machines to build a Genomic Scar (GS) model to predict HRD events, and Kaplan-Meier analyses were performed by comparing the progression-free survival (PFS) of patients in different groups using a two-sided log-rank test. MAIN OUTCOME MEASURES: The performance of the GS model and the result of clinical validation. RESULTS: The GS model displayed more than 97.0% sensitivity to detect BRCA-deficient events, and the GS model identified patients that could benefit from poly(ADP-ribose) polymerase inhibitors (PARPi), as the GS score (GSS)-positive group had a longer progression-free survival (PFS) (9.4 versus 4.4 months; hazard ratio [HR] = 0.54, P < 0.001) than the GSS-negative group after PARPi treatment. Meanwhile, the GSS showed high concordance among different NGS panels, which implied the robustness of the GS model. CONCLUSIONS: The GS was a robust model to predict HRD and had broad clinical applications in predicting which patients will respond favourably to PARPi treatment.
引用
- Yuan W, Ni J, Wen H, et al. Genomic Scar Score: A robust model predicting homologous recombination deficiency based on genomic instability. BJOG. 2022. PMID: 36485068. doi:10.1111/1471-0528.17324
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。